By continuing to use the site you agree to our Privacy & Cookies policy

NICE questions new diabetes drug’s cost effectiveness  

The National Institute for Health and Care Excellence has called for more evidence from Boehringer Ingelheim on its drug empagliflozin for treating type 2 diabetes.

Get unlimited access

As a subscriber you will benefit from:

  • Full online and mobile access to news and opinion stories
  • Customised email alerts straight to your inbox (over 30 alerts available)
  • 4,500 practice articles in our archive 
  • Over £500 worth of CPD learning units 
or

newsletterpromo